Cross-reactive influenza-specific antibody-dependent cellular cytotoxicity in intravenous immunoglobulin as a potential therapeutic against emerging influenza viruses

Journal of Infectious Diseases

Volumn 210, Issue 11, 2014, Pages 1811-1822

  Jegaskanda, Sinthujan ^a   Vandenberg, Kirsten ^b   Laurie, Karen L ^c   Loh, Liyen ^a   Kramski, Marit ^a   Winnall, Wendy R ^a   Kedzierska, Katherine ^a   Rockman, Steven ^a,b   Kent, Stephen J ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b BioCSL   (Australia)

^c VICTORIAN INFECTIOUS DISEASES REFERENCE LABORATORY   (Australia)

Author keywords

ADCC; Influenza; IVIG; NK cells; Swine origin influenza virus

Indexed keywords

CROSS REACTING ANTIBODY; IMMUNOGLOBULIN; INFLUENZA VIRUS HEMAGGLUTININ; SIALIDASE; VIRUS ANTIBODY;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY SPECIFICITY; ARTICLE; CONTROLLED STUDY; CROSS REACTION; HEMAGGLUTINATION INHIBITION; INFLUENZA; INFLUENZA A VIRUS (H1N1); INFLUENZA A VIRUS (H5N1); INFLUENZA A VIRUS (H7N9); INFLUENZA VIRUS; MOLECULAR RECOGNITION; NONHUMAN; PANDEMIC INFLUENZA; PRIORITY JOURNAL; VIRUS STRAIN; ADULT; AGED; BLOOD; FEMALE; HEMAGGLUTINATION TEST; HUMAN; IMMUNOLOGY; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H7N9; INFLUENZA, HUMAN; MALE; MIDDLE AGED; NATURAL KILLER CELL; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, VIRAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; CROSS REACTIONS; FEMALE; HEMAGGLUTINATION TESTS; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H7N9 SUBTYPE; INFLUENZA, HUMAN; KILLER CELLS, NATURAL; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 84922324388     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiu334     Document Type: Article

References (44)

1. O'Brien KB, Morrison TE, Dundore DY, Heise MT, Schultz-Cherry S. A protective role for complement C3 protein during pandemic 2009 H1N1 and H5N1 influenza A virus infection. PLoS One 2011; 6:e17377.
2. Ohta R, Torii Y, Imai M, Kimura H, Okada N, Ito Y. Serum concentrations of complement anaphylatoxins and proinflammatory mediators in patients with 2009 H1N1 influenza. Microbiol Immunol 2011; 55:191-8.
3. Chowell G, Bertozzi SM, Colchero MA, et al. Severe respiratory disease concurrent with the circulation of H1N1 influenza. N Engl J Med 2009; 361:674-9.
4. Dawood FS, Iuliano AD, Reed C, et al. Estimated global mortality associated with the first 12 months of 2009 pandemic influenza A H1N1 virus circulation: a modelling study. Lancet Infect Dis 2012; 12:687-95.
5. Dawood FS, Jain S, Finelli L, et al. Emergence of a novel swine-origin influenza A(H1N1) virus in humans. N Engl J Med 2009; 360:2605-15.
6. Borse RH, Shrestha SS, Fiore AE, et al. Effects of vaccine program against pandemic influenza A(H1N1) virus, United States, 2009-2010. Emerg Infect Dis 2013; 19:439-48.
7. Shrestha SS, Swerdlow DL, Borse RH, et al. Estimating the burden of 2009 pandemic influenza A (H1N1) in the United States (April 2009-April 2010). Clin Infect Dis 2011; 52(suppl 1):S75-82.
8. Partridge J, Kieny MP. Global production of seasonal and pandemic (H1N1) influenza vaccines in 2009-2010 and comparison with previous estimates and global action plan targets. Vaccine 2010; 28:4709-12.
9. Lu PJ, Ding H, Euler GL, et al. Interim results: state-specific influenza A (H1N1) 2009 monovalent vaccination coverage-United States, October 2009-January 2010. MMWR Morb Mortal Wkly Rep 2010; 59:363-8.
10. Huber VC, Lynch JM, Bucher DJ, Le J, Metzger DW. Fc receptor-mediated phagocytosis makes a significant contribution to clearance of influenza virus infections. J Immunol 2001; 166:7381-8.
11. Laidlaw BJ, Decman V, Ali MA, et al. Cooperativity between CD8+ T cells, non-neutralizing antibodies, and alveolar macrophages is important for heterosubtypic influenza virus immunity. PLoS Pathog 2013; 9:e1003207.
12. Hashimoto G, Wright PF, Karzon DT. Antibody-dependent cell-mediated cytotoxicity against influenza virus-infected cells. J Infect Dis 1983; 148:785-94.
13. Hashimoto G, Wright PF, Karzon DT. Ability of human cord blood lymphocytes to mediate antibody-dependent cellular cytotoxicity against influenza virus-infected cells. Infect Immun 1983; 42:214-8.
14. Greenberg SB, Criswell BS, Six HR, Couch RB. Lymphocyte cytotoxicity to influenza virus-infected cells: response to vaccination and virus infection. Infect Immun 1978; 20:640-5.
15. Vella S, Rocchi G, Resta S, Marcelli M, De Felici A. Antibody reactive in antibody-dependent cell-mediated cytotoxicity following influenza virus vaccination. J Med Virol 1980; 6:203-11.
16. Sorn S, Sok T, Ly S, et al. Dynamic of H5N1 virus in Cambodia and emergence of a novel endemic sub-clade. Infect Genet Evol 2013; 15:87-94.
17. Ranji SR, Shetty K, Posley KA, et al. Closing the quality gap: a critical analysis of quality improvement strategies (Vol 6: prevention of healthcare-associated infections). Rockville, MD: Agency for Healthcare Research and Quality, 2007.
18. Jegerlehner A, Schmitz N, Storni T, Bachmann MF. Influenza Avaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity. J Immunol 2004; 172:5598-605.
19. Dilillo DJ, Tan GS, Palese P, Ravetch JV. Broadly neutralizing hemagglutinin stalk-specific antibodies require Fcgamma R interactions for protection against influenza virus in vivo. Nat Med 2014; 20:143-51.
20. Corti D, Voss J, Gamblin SJ, et al. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science 2011; 333:850-6.
21. Aghamohammadi A, Moin M, Farhoudi A, et al. Efficacy of intravenous immunoglobulin on the prevention of pneumonia in patients with agammaglobulinemia. FEMS Immunol Med Microbiol 2004; 40:113-8.
22. Hemming VG. Use of intravenous immunoglobulins for prophylaxis or treatment of infectious diseases. Clin Diagn Lab Immunol 2001; 8:859-63.
23. Tacke CE, Smits GP, van der Klis FR, Kuipers IM, Zaaijer HL, Kuijpers TW. Reduced serologic response to mumps, measles, and rubella vaccination in patients treated with intravenous immunoglobulin for Kawasaki disease. J Allergy Clin Immunol 2013; 131:1701-3.
24. Ferrara G, Zumla A, Maeurer M. Intravenous immunoglobulin (IVIg) for refractory and difficult-to-treat infections. Am J Med 2012; 125:1036 e1-8.
25. Hong DK, Tremoulet AH, Burns JC, Lewis DB. Cross-reactive neutralizing antibody against pandemic 2009 H1N1 influenza a virus in intravenous immunoglobulin preparations. Pediatr Infect Dis J 2011; 30:67-9.
26. Lemaitre M, Leruez-Ville M, De Lamballerie XN, et al. Seasonal H1N1 2007 influenza virus infection is associated with elevated pre-exposure antibody titers to the 2009 pandemic influenza A (H1N1) virus. Clin Microbiol Infect 2011; 17:732-7.
27. Kreil TR, Mc Vey JK, Lei LS, et al. Preparation of commercial quantities of a hyperimmune human intravenous immunoglobulin preparation against an emerging infectious disease: the example of pandemic H1N1 influenza. Transfusion 2012; 52:803-9.
28. Hung IF, To KK, Lee CK, et al. Hyperimmune IV immunoglobulin treatment: a multicenter double-blind randomized controlled trial for patients with severe 2009 influenza A(H1N1) infection. Chest 2013; 144:464-73.
29. Jegaskanda S, Job ER, Kramski M, et al. Cross-reactive influenza-specific antibody-dependent cellular cytotoxicity antibodies in the absence of neutralizing antibodies. J Immunol 2013; 190:1837-48.
30. Gerentes L, Kessler N, Thomas G, Aymard M. Simultaneous purification of influenza haemagglutinin and neuraminidase proteins by immunochromatography. J Virol Methods 1996; 58:155-65.
31. McVernon J, Laurie K, Nolan T, et al. Seroprevalence of 2009 pandemic influenza A(H1N1) virus in Australian blood donors, October - December 2009. Euro Surveill 2010; 15:pii:19678.
32. Jegaskanda S, Weinfurter JT, Friedrich TC, Kent SJ. Antibody-dependent cellular cytotoxicity is associated with control of pandemic H1N1 influenza virus infection of Macaques. J Virol 2013; 87: 5512-22.
33. Miller MS, Tsibane T, Krammer F, et al. 1976 and 2009 H1N1 influenza virus vaccines boost anti-hemagglutinin stalk antibodies in humans. J Infect Dis 2013; 207:98-105.
34. Krammer F, Pica N, Hai R, Tan GS, Palese P. Hemagglutinin stalk-reactive antibodies are boosted following sequential infection with seasonal and pandemic H1N1 influenza virus in mice. J Virol 2012; 86:10302-7.
35. Sui J, Sheehan J, Hwang WC, et al. Wide prevalence of heterosubtypic broadly neutralizing human anti-influenza A antibodies. Clin Infect Dis 2011; 52:1003-9.
36. Corti D, Lanzavecchia A. Broadly neutralizing antiviral antibodies. Annu Rev Immunol 2013; 31:705-42.
37. Gao R, Cao B, Hu Y, et al. Human infection with a novel avian-origin influenza A (H7N9) virus. N Engl J Med 2013; 368:1888-97.
38. Gao HN, Lu HZ, Cao B, et al. Clinical findings in 111 cases of influenza A (H7N9) virus infection. N Engl J Med 2013; 368:2277-85.
39. Hai R, Schmolke M, Leyva-Grado VH, et al. Influenza A(H7N9) virus gains neuraminidase inhibitor resistance without loss of in vivo virulence or transmissibility. Nat Commun 2013; 4:2854.
40. Corti D, Suguitan AL Jr, Pinna D, et al. Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine. J Clin Invest 2010; 120:1663-73.
41. Gioia C, Castilletti C, Tempestilli M, et al. Cross-subtype immunity against avian influenza in persons recently vaccinated for influenza. Emerg Infect Dis 2008; 14:121-8.
42. Garcia JM, Pepin S, Lagarde N, et al. Heterosubtype neutralizing responses to influenza A (H5N1) viruses are mediated by antibodies to virus haemagglutinin. PLoS One 2009; 4:e7918.
43. Li Q, Zhou L, Zhou M, et al. Preliminary report: epidemiology of the avian influenza A (H7N9) outbreak in China. N Engl J Med 2014; 370:520-32.
44. Kashyap AK, Steel J, Oner AF, et al. Combinatorial antibody libraries from survivors of the Turkish H5N1 avian influenza outbreak reveal virus neutralization strategies. Proc Natl Acad Sci U S A 2008; 105:5986-91.